Novartis Neuroscience Academy
Summary
- Treatment switch from Gilenya® to Kesimpta®
- Early switch from teriflunomide to Kesimpta®
- Treatment switch from Gilenya® to Kesimpta®
- First line switch from dimethyl fumarate to Kesimpta®
- Increased tolerability: ocrelizumab to Kesimpta®
- Treatment switch from cladribine, to Kesimpta®
Treatment switch from Gilenya® to Kesimpta®
Reduce the rebound risk after Gilenya® cessation with a switch to Kesimpta® - Dutch spoken with English subtitles
Early switch from teriflunomide to Kesimpta®
Discover the benefits to use Kesimpta® early on - FR spoken with English subtitles
Treatment switch from Gilenya® to Kesimpta®
Discover the benefits of anti-CD20 subcutaneous administration after Gilenya® cessation - FR spoken with English subtitles
Shifting paradigms: Journey from Fingolimod to Ofatumumab - NL spoken
First line switch from dimethyl fumarate to Kesimpta®
Discover the benefits to use Kesimpta® early on - FR spoken with English subtitles
Increased tolerability: ocrelizumab to Kesimpta®
The increased tolerability from Kesimpta® over ocrelizumab thanks to absence of pre-medication - FR spoken with English subtitles
Treatment switch from cladribine, to Kesimpta®
Switch from Cladribine to Kesimpta ® due to a disease re-activation - Dutch spoken with English subtitles
FA-11258311 - 23/08/2024